On April 1, 2025, Stryker announced the completion of the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC. This transaction establishes VB Spine, LLC as a newly formed, standalone company. The divestiture is a strategic move by Stryker to enhance its focus and invest in areas with the greatest opportunity for innovation and long-term growth.
Kevin Lobo, Chair and CEO of Stryker, stated that the sale positions the company to meet evolving customer needs more effectively. Stryker will maintain its commitment to the spine space through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses. A strategic partnership with VB Spine ensures continued access to Mako Spine and Copilot for use with VB Spine’s implants in spine procedures.
While the U.S. business transfer is complete, certain international markets are expected to transition to VB Spine at later dates, subject to legal and regulatory requirements. This divestiture allows Stryker to streamline its portfolio, exiting a lower-growth segment while retaining a strategic connection to key enabling technologies in the spine market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.